REFERENCES
- Porter J B. A risk-benefit assessment of iron-chelation therapy. Drug Safety 1997; 17: 407–421
- Cragg L, Hebbel R P, Miller W, et al. The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood 1998; 92: 632–638
- Kontoghiorghes G J. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Toxicol Lett 1995; 80: 1–18
- Richardson D R, Ponka P. Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am J Hematol 1998; 58: 299–305
- Iversen P L, Copple B L, Tewary H K. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicol Lett 1995; 82–83: 425–430
- Copple B L, Gmeiner W M, Iversen P L. Reaction between metabolically activated acetaminophen and phosphorothioate oligonucleotides. Toxicol Appl Pharmacol 1995; 133: 53–63
- Bishop M R, Iversen P L, Bayever E, et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies [see comments]. J Clin Oncol 1996; 14: 1320–1326
- Tewary H K, Iversen P L. Qualitative and quantitative measurements of oligonucleotides in gene therapy: Part II in vivo models. J Pharm Biomed Ana 1997; 15: 1127–1135
- Levin A A, Monteith D K, Leeds J M, et al. Toxicity of oligonucleotide therapeutic agents. Antisense Research and Application, S T Crooke. Springer-Verlag, Berlin 1998; 169–215
- Krieg A M, Yi A K, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546–549
- Brand R M, Wahl A, Iversen P L. Effects of size and sequence on the iontophoretic delivery of oligonucleotides. J Pharm Sci 1998; 87: 49–52